- Home
- YSG vs VCRE Comparison
YSG vs VCRE Comparison
Compare YSG & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | YSG | VCRE |
|---|---|---|
| Founded | 2016 | N/A |
| Country | China | Sweden |
| Employees | N/A | 40 |
| Industry | Package Goods/Cosmetics | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.9M | 316.4M |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | YSG | VCRE |
|---|---|---|
| Price | $2.66 | $11.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 62.7K | 8.3K |
| Earning Date | 05-15-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.08 | N/A |
| Revenue Next Year | $9.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $10.47 |
| 52 Week High | $10.28 | $13.15 |
Technical Indicators
Market Signals| Indicator | YSG | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 24.11 | 46.13 |
| Support Level | $2.15 | $10.83 |
| Resistance Level | $3.49 | $13.00 |
| Average True Range (ATR) | 0.18 | 0.75 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 4.29 | 40.30 |
Price Performance
Historical ComparisonAbout YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands. Geographically, company operates in PRC, Europe and US regions.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.